Add To Watchlist
Share URL
About The Company
Description
Coloplast A/S develops, manufactures, and markets medical products.
Read More
Overview
Value
10
Growth
38
Health
50
Management
69
Analyst Opinion
89
Total
51
All Scores Out Of 100
Best Features
- Liked by analysts
- Has strong dividend growth
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- There is a history of diluting shareholders
- Has a high level of debt
- No margin of safety at their current market price
- Poor earnings and cashflow growth
- Price-to-earnings ratio of 38.2 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Market Peers
CBHD.DE
Key Figures
PE Ratio (TTM)
38.21
Margin Of Safety (DCF)
-51.82%
Revenue Growth (5 Year Average)
9.06%
Ratings Consensus
Strong Buy
Share Buybacks
-0.05%
Dividend Yeild (TTM)
2.25%
Valuation
Value Score
10
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 479.3 EUR ✔
Current Price: 113.7 EUR
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
38.21x
Free Cashflow Yeild
2.21%
PE/Earnings Growth
N/A
Price/Book
2.90x
Growth
Growth Score
38
- ✔ Revenue growth has improved this yeara
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 9.06% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 8.16% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 2.88% is lower than the market average (12.35%)
Revenue Growth
9.06%
Earnings Growth
8.16%
Cashflow Growth
2.88%
Health
Health Score
50
Altman Z Score
2.05
Piostroski Score
6.00
Debt/Equity
2.26x
Current Assets/Liabilities
1.20x
Free Cashflow/Total Debt
0.21x
Debt/Capital
2.13x
Dividend
Secure Dividend Score
50
- ✔ Dividend yeild of 2.25% is more than the market average (1.85%)
- ✘ At risk of being unsafe
- ✔ Dividends have shown growth over the last 5 years
- ✘ Long term dividend payout ratio of 84.91% is high and may limit growth
- ✘ Payout ratio (TTM) of 85.87% is higher than the average (40%)
- ✘ Dividend growth has been slowing recently
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
2.25%
Dividend Growth
5.51%
Payout Ratio (Earnings)
85.87%
Payout Ratio (Cashflow)
101.94%
Management
Management Score
69
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✔ Return-on-equity of 56.57% is higher than the market average (15%)
- ✔ Return-on-capital-employed of 19.29% is higher than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
Average Buybacks/Dilution
-0.05%
Recent Buybacks/Dilution
-0.33%
5 Year Price Volitility
20.73%
Return On Assets
13.42%
Return On Capital Employed
19.29%
Return On Equity
56.57%
Return On Free Cashflow
141.11%
Return On Investments
9197.07%
Analysts
Analyst Opinion
89
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Coloplast A/S
Currency
EUR
Beta
0.80238
Vol Avg
157
Ceo
Cik
Cusip
K16018192
Exchange
XETRA
Full Time Employees
12000
Industry
Health Care Equipment & Services
Sector
Healthcare
Ipo Date
1983-01-01
Address
Holtedam 1-3
City
Humlebaek
State
Country
DK
Zip
Phone
4549111111
All financial data provided by FMP